Eledon reports data from ongoing phase 1b trial evaluating tegoprubart in patients undergoing kidney transplantation at world congress of nephrology

Results from three participants demonstrated no incidence of acute rejection at durations of 56, 154, and 232 days

ELDN Ratings Summary

ELDN Quant Ranking